LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Bridgebio Pharma Inc

Fechado

SetorSaúde

38.57 0.6

Visão Geral

Variação de preço das ações

24h

Atual

Mín

38.16

Máximo

39.27

Indicadores-chave

By Trading Economics

Rendimento

100M

-167M

Vendas

111M

117M

EPS

-0.989

Margem de lucro

-143.546

Funcionários

725

EBITDA

109M

-126M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+57.8% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-106M

6.7B

Abertura anterior

37.97

Fecho anterior

38.57

Sentimento de Notícias

By Acuity

18%

82%

34 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Bridgebio Pharma Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

12 de set. de 2024, 17:01 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 de set. de 2024, 11:00 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Bridgebio Pharma Inc Previsão

Preço-alvo

By TipRanks

57.8% parte superior

Previsão para 12 meses

Média 60.5 USD  57.8%

Máximo 95 USD

Mínimo 42 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Bridgebio Pharma Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

14

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

34.71 / 36.9Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

34 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.